10-QPeriod: Q3 FY2001

QUEST DIAGNOSTICS INC Quarterly Report for Q3 Ended Sep 30, 2001

Filed October 31, 2001For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) reported strong financial performance for the nine months ended September 30, 2001, with net income increasing to $111.4 million from $76.7 million in the prior year period. This growth was driven by revenue increases, improved operating efficiencies stemming from the integration of SmithKline Beecham Clinical Laboratories (SBCL), and a reduction in net interest expense following a significant debt refinancing in the second quarter of 2001. Despite an extraordinary loss of $21.6 million related to the debt refinancing, the company demonstrated robust operational improvements. The company is also strategically positioning itself for future growth through key acquisitions, including MedPlus, Inc. and Clinical Diagnostic Services, Inc., and is preparing for the adoption of new accounting standards for goodwill and intangible assets that are expected to reduce future amortization expenses.

Key Highlights

  • 1Net income for the first nine months of 2001 rose to $111.4 million, a significant increase from $76.7 million in the same period of 2000.
  • 2Revenue growth was driven by improvements in average revenue per requisition, partly due to better pricing, a favorable test mix, and a shift in payer mix.
  • 3Significant debt refinancing in June 2001 lowered overall interest costs and reduced outstanding debt levels, contributing to lower net interest expense.
  • 4The company is progressing with its SBCL integration plan, anticipating $150 million in annual synergies by the end of 2002, with $120 million already achieved in annual run-rate synergies by Q3 2001.
  • 5An extraordinary loss of $21.6 million was recorded in the nine-month period due to debt refinancing costs, including deferred financing costs and tender premiums.
  • 6Capital expenditures for the nine months totaled $110.2 million, and the company made strategic acquisitions, notably Clinical Laboratories of Colorado, LLC, for $47.0 million.
  • 7The company is anticipating a reduction in future amortization expenses of approximately $35 million annually starting in 2002 due to the adoption of new accounting standards for goodwill and intangible assets.

Frequently Asked Questions

Quest Diagnostics showed strong financial performance, with net income increasing to $111.4 million for the nine months ended September 30, 2001, compared to $76.7 million for the same period in 2000. This represents a significant increase, driven by revenue growth and improved operational efficiencies.

In the second quarter of 2001, Quest Diagnostics completed a major debt refinancing, issuing $550 million in senior notes and entering into a new $500 million credit facility. This transaction led to the repayment of existing debt and the settlement of interest rate swap agreements. While this refinancing reduced future interest expenses, it also resulted in an extraordinary loss of $36.0 million ($21.6 million net of taxes) due to write-offs of deferred financing costs and tender premiums.

The integration of SBCL is largely complete, with the company having finished facility and infrastructure consolidations by June 30, 2001. Quest Diagnostics continues to expect significant annual synergies of $150 million from this integration, with an annual run-rate of approximately $120 million achieved by the end of the third quarter of 2001.

Yes, Quest Diagnostics will adopt new accounting standards SFAS 141 and SFAS 142 regarding business combinations and goodwill/intangible assets starting January 1, 2002. The adoption of these standards is expected to reduce annual amortization expenses for intangible assets by approximately $35 million, as purchased goodwill will no longer be amortized but will be subject to impairment testing.